iBio (IBIO) Corporate presentation summary

Market landscape and unmet needs

• Incretin class agonists like GLP-1 have transformed obesity treatment, with over 10% of American adults using them, but challenges remain in durability, lean mass preservation, and tolerability.

• Weight loss with GLP-1s often results in loss of lean tissue and increased risk of frailty fractures upon weight regain.

• There is a shift toward therapies that improve quality of weight loss, sustain results, and reduce side effects.

Pipeline and lead programs

• Lead programs include IBIO-610 (Activin E antibody), Myostatin x Activin A bispecific antibody, and IBIO-600 (long-acting myostatin antibody).

• IBIO-610 targets fat-specific weight loss and maintenance post-GLP-1, with IND filing expected 2H 2026 and Phase 1 in 1H 2027.

• Myostatin x Activin A bispecific aims to enhance muscle growth and quality of weight loss, with IND filing in 1H 2027.

• IBIO-600 is designed for muscle mass preservation, with IND filing in 1H 2026.

IBIO-610: Activin E antibody

• Activin E is a hepatokine linked to adiposity and diabetes risk; genetic loss reduces fat and disease risk.

• IBIO-610 shows potent inhibition of Activin E, induces fat-selective weight loss in obese mice, and preserves lean mass.

• Demonstrates synergistic weight loss with GLP-1 agonists and prevents weight regain after GLP-1 cessation in preclinical models.

• Non-human primate PK data suggest potential for twice-yearly dosing in humans.